CClinicalTrials.gg
RecruitingNCT06817980sensdesoiUpdated Aug 20, 2026

Disorders of the Sense of Self and Physical Activity

An interventional study of Physical activity in SCHIZOPHRENIA 1 (Disorder), Borderline Personality Disorder and Vestibular Syndromes, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by University Hospital, Strasbourg, France · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
168
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Schizophrenia (SZ) patients with metabolic syndrome, patients with vestibular syndrome, and patients with borderline personality disorder, would benefit from physical activity (PA). Yet patient adherence to PA is low, at least in the case of SZ. the investigators work and the literature lead the investigators to consider that, in addition to motivational aspects, disorders of the bodily sense of self could play a role in this lack of adherence. Simply walking involves visual movements related to the self, which must be distinguished from movements in the environment. This means a distinction between self and not-self. Furthermore, these movements are all the more difficult to distinguish as they may also result from the fact that hidden objects become visible as a result of our own movement. In all sense-of-self disorders can themselves affect physical training, and the investigators will measure them in the first stage. In the second stage, the investigators will apply a standard, risk-free PA protocol by walking (3x3 sessions of 30 min). the investigators will test the impact of physical training on the sense of self under different conditions, with one environment minimizing self-related movement, vs. 2 environments with a variable level of enrichment (i.e. hidden objects inducing more or less self-related movement).

At the end of the protocol, the investigators will offer participants who wish to take part in an ancillary study, i.e. a walking session with mixed-reality goggles. These will superimpose a luminous flux on the periphery of the visual field. According to results obtained in the laboratory, this flux could restore sensory mechanisms impaired in schizophrenia. the investigators will use these glasses in the most difficult condition for the patient, and verify their impact.

02

Conditions studied

  • SCHIZOPHRENIA 1 (Disorder)
  • Borderline Personality Disorder
  • Vestibular Syndromes
03

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Criteria common to all participants:
  • Men or women aged 18 to 60 inclusive
  • Subject affiliated to a health insurance scheme, beneficiary or beneficiary's beneficiary
  • Able to understand the aims and risks of the research, and to give informed consent
  • Visual acuity > 0.7 on the Freiburg Vision Test (Bach 1996) due to the use of visual equipment
  • BMI (body mass index) \< 40 (due to cardiovascular risk).

Patient-specific criteria:

  • With schizophrenia: criteria for schizophrenia as defined in the DSMV (American Psychiatric Association, 2015)
  • With borderline personality disorder: criteria for borderline personality disorder as defined in the DSMV (American Psychiatric Association, 2015)
  • With vestibular disorders: peripheral vestibular disorders established after otolaryngological examination

Exclusion criteria

Exclusion Criteria:

  • Criteria common to all participants:
  • Serious or unstabilized somatic pathology (including cardiovascular)
  • History likely to affect cerebral anatomy or to be linked to an abnormality (neonatal suffering, neurosurgical operation, comitiality, stroke...)
  • Presence of joint pain, likely to worsen after exercise
  • - Substance use disorders (as defined by DSM-IV TR)
  • 3D vision disorders as measured by the Wirt stereotest (depth perception at a disparity of at least 80'' arc)
  • Movement perception disorders (correct movement discrimination in less than 75% of trials (cf. § V-2.2)
  • History of general anaesthesia in the 3 months preceding the study
  • History of neurological disease
  • Impossibility of giving the subject informed information (subject in emergency situation)
  • Pregnancy declared by patient
  • Breast-feeding
  • Subject in exclusion period (determined by a previous or current study)
  • Subject hospitalized
  • Subject under court protection

Exclusion criteria specific to control subjects or patients with vestibular syndrome:

History of major psychiatric pathology with current psychotropic medication (i.e., antidepressant, thymoregulator, antipsychotic)

04

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
168 participants (estimated)

Study arms

  • Experimental
    Self and physical activity protocol

    Behavioral: Physical activity

Interventions

  • BehavioralPhysical activity

    \- Physical activity: We will compare the impact of 3 different environments (with no object in the environment, vs. with some objects but no hidden objects vs. with objects at the fore- and background) during (total of 9 sessions of 30 minutes + 3\*5 minutes of testing), on the measure of self (see below). Visit 10: We will repeat a walking session. Participants will wear mixed-reality goggles, which allow them to visualize the environment and superimpose a continuous stream of light. This session is intended to test the idea that this flow would enable SZ patients to suffer less from the discontinuous appearance of information when moving around. Measure of 'self' : the participants will decide whether the line presented on a computer screen is static or moving. They will be immobile, walking on the spot in front of the computer, or passively mobilized with a whole-body movement platform. The latter condition will be used only in the first phase of the protocol

05

What researchers measure

Primary outcomes

  1. Impact of physical activity on the 'self' measure

    Quantification of the d' index, which represents the ability to discriminate between moving and static lines (whose movement is only related to one's own displacement, which induces a mirror movement on the retina). The d' will be measured three times per PA session, and in all 3 sessions per condition (neutral vs. enriched, with increasing complexity of self-related movements). The evaluation criterion will be the evolution of the d' index over the course of the PA training sessions in the 3 conditions.

    Time frame: Day 0

  2. Impact of physical activity on the 'self' measure

    Quantification of the d' index, which represents the ability to discriminate between moving and static lines (whose movement is only related to one's own displacement, which induces a mirror movement on the retina). The d' will be measured three times per PA session, and in all 3 sessions per condition (neutral vs. enriched, with increasing complexity of self-related movements). The evaluation criterion will be the evolution of the d' index over the course of the PA training sessions in the 3 conditions.

    Time frame: between Day 0 and Month 3

06

Study locations

1 of 1 sites recruiting
  • Service de psychiatrie
    Strasbourg, 67000, France
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06817980
Lead sponsor
University Hospital, Strasbourg, France
Responsible party
Sponsor
First posted
Feb 10, 2025
Start date
Aug 11, 2025
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Aug 20, 2026

Study contacts

Sarah Hustache
Contact
dpidrci@chru-strasbourg.fr
0388116768
Marius Teletin, MD
Contact
marius.teletin@chru-strasbourg.fr

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion